스포츠 의학용 혈액 기반 바이오마커 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 지역별, 부문별 예측(2024-2030년)

Blood-based Biomarker For Sports Medicine Market Size, Share & Trends Analysis Report By Type (CK, Myoglobin, Lactate, WBC, Urea, CRP), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,245,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,631,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,402,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

스포츠 의학용 혈액 기반 바이오마커 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 스포츠 의학용 혈액 기반 바이오마커 세계 시장 규모는 2030년까지 11억 6,000만 달러에 달하고, 2024년에서 2030년까지 연평균(CAGR) 6.7%로 확대될 것으로 예상됩니다.

개인화된 건강에 대한 관심 증가, 바이오마커 기술의 발전, 정확한 성능 및 회복 평가에 대한 수요 증가가 이 시장을 이끄는 주요 요인입니다. 또한, 스포츠 관련 부상에 대한 인식이 높아지고 정밀 진단에 대한 필요성이 높아지면서 시장 성장과 혁신에 기여하고 있습니다.

연구 개발의 중요성이 높아지고 스포츠 의학에 대한 투자가 증가하면서 시장 확대에 큰 힘을 보태고 있습니다. 스포츠 의학 분야가 발전함에 따라 첨단 바이오마커를 통해 운동선수의 복잡한 생리적 반응을 이해하는 데 많은 관심이 집중되고 있습니다. 스포츠 의학 연구에 대한 투자는 혈액 기반 바이오마커 기술의 눈부신 발전을 촉진하고 있습니다. 기업과 연구기관들은 바이오마커의 검출과 해석을 개선하기 위해 고처리량 스크리닝 방법 및 고급 데이터 분석 개발에 많은 투자를 하고 있습니다. 공공 및 민간 기관의 투자 증가는 스포츠 의학 분야에서 고급 바이오마커에 대한 수요를 더욱 촉진하고 있습니다.

또한, 부상 위험을 미리 예측하기 위해 바이오마커의 예측 가능성도 연구되고 있는데, Frontiers in Physiology 저널에 게재된 연구에 따르면, 부상 감수성을 예측하기 위해 산화 스트레스와 염증의 바이오마커에 초점을 맞춘 선행 연구가 진행 중입니다. 예측하는 데 초점을 맞추었습니다. 이러한 예측 능력은 예방 전략에 가치가 있으며, 운동선수가 사전 예방 조치를 통해 부상을 예방하는 데 도움이 될 수 있습니다. 그 결과, 스포츠 의학의 혈액 기반 바이오마커 시장은 크게 성장하고 있습니다.

스포츠 의학용 혈액 기반 바이오마커 시장 보고서 - 하이라이트

• 크레아틴 키나아제(CK) 부문은 2023년 18.0%로 가장 큰 매출 점유율을 차지했으며, CK 검사에 대한 수요는 부상 예방 및 관리에 대한 관심이 높아지면서 운동선수 및 스포츠 팀의 과훈련 방지 및 회복 최적화의 중요성에 대한 인식이 높아짐에 따라 증가하고 있는 것이 배경이 되고 있습니다.
• 스포츠 의학용 혈액 기반 바이오마커 시장에서 활동하는 주요 기업으로는 Abbott, BIOMERIEUX, F. Hoffmann-La Roche Ltd, RayBiotech, Inc. 등이 있습니다. 또한, 신흥국 시장에서는 신규 시장 진출기업들의 혁신적인 신제품 출시와 주요 시장 진출기업들 간의 전략적 제휴를 통한 신제품 개발이 활발히 이루어지고 있습니다.
• 2023년 3월, Abbott는 미국 FDA로부터 TBI에 대한 최초의 시판용 혈액 검사를 승인받아 미국 병원에서 널리 사용할 수 있게 되었습니다. 이 검사는 혈액에서 두 가지 바이오 마커를 감지하는 것으로, 이러한 바이오 마커가 높은 수치로 존재할 경우 뇌 손상과 밀접한 관련이 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 스포츠 의학용 혈액 기반 바이오마커 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 스포츠 의학용 혈액 기반 바이오마커 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석

제4장 스포츠 의학용 혈액 기반 바이오마커 시장 : 유형별 추정·동향 분석

• 세계의 스포츠 의학용 혈액 바이오마커 시장 : 유형별 대시보드
• 세계의 스포츠 의학용 혈액 바이오마커 시장 : 유형별 변동 분석
• 세계의 스포츠 의학용 혈액 바이오마커 시장 : 유형별 매출
• CK
• 미오글로빈
• 젖산
• WBC
• 요소
• CRP
• 지질 및 단백질 하이드로퍼옥시드
• IL-6
• 기타

제5장 스포츠 의학용 혈액 기반 바이오마커 시장 : 유형별 지역별 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제6장 경쟁 구도

• 기업/경쟁 분류
• 벤더 구도
  • 주요 유통업체 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석, 2023년
  • Abbott
  • BIOMERIEUX
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories
  • Siemens Healthineers AG
  • RayBiotech, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Randox Laboratories Ltd.

LSH

영문 목차

영문목차

Blood-Based Biomarker For Sports Medicine Market Growth & Trends:

The global blood-based biomarker for sports medicine market size is anticipated to reach USD 1.16 billion by 2030 and is anticipated to expand at a CAGR of 6.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing focus on personalized health, advancements in biomarker technology, and growing demand for accurate performance & recovery assessments. Moreover, rising awareness of sports-related injuries and the need for precise diagnostics also contribute to market growth & innovation.

The growing emphasis on R&D and rising investments in sports medicine are significantly driving the market expansion. As the sports medicine field evolves, there is an increasing focus on understanding the complex physiological responses of athletes through advanced biomarkers. Investment in sports medicine research is promoting significant advancements in blood-based biomarker technologies. Companies and research institutions are investing heavily in developing high-throughput screening methods and advanced data analytics to improve biomarker detection and interpretation. The growing investment from public and private organizations further propels the demand for advanced biomarkers in sports medicine.

Moreover, the predictive potential of biomarkers is also being investigated to predict injury risks before they occur. According to research published in Frontiers in Physiology, advanced research focuses on oxidative stress and inflammation biomarkers to predict injury susceptibility. This predictive capability is valuable for preventive strategies, helping athletes avoid injuries through proactive measures. As a result, the market for blood-based biomarkers in sports medicine is experiencing significant growth.

Blood-Based Biomarker For Sports Medicine Market Report Highlights:

• The creatine kinase (CK) segment accounted for the largest revenue share at 18.0% in 2023. The demand for CK testing is driven by the increasing focus on injury prevention and management and increasing awareness among athletes & sports teams about the importance of preventing overtraining and optimizing recovery
• Some of the key players operating in the blood-based biomarkers for sports medicine market are Abbott, BIOMERIEUX, F. Hoffmann-La Roche Ltd., ARUP Laboratories, Siemens Healthineers AG, and RayBiotech, Inc. Furthermore, the market is witnessing the emergence of new and innovative products from new players, as well as strategic partnerships among key market players to develop new offerings
• In March 2023, Abbott obtained clearance from the U.S. FDA for the first commercially available laboratory blood test for TBI, allowing it to be widely accessible in U.S. hospitals. The test detects two biomarkers in the blood, which, when present at elevated levels, are strongly associated with brain injury

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood-based Biomarker for Sports Medicine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing Demand for Personalized Medicine
    • 3.2.1.2. Increased Focus on Injury Prevention and Recovery
    • 3.2.1.3. Growing R&D and Rising Investments in Sports Medicine s
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory Challenges and Lack of Awareness & Standardization
• 3.3. Blood-based Biomarker for Sports Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Blood-based Biomarker for Sports Medicine Market: Type Estimates & Trend Analysis

• 4.1. Global Blood-based Biomarker for Sports Medicine Market: Type Dashboard
• 4.2. Global Blood-based Biomarker for Sports Medicine Market: Type Movement Analysis
• 4.3. Global Blood-based Biomarker for Sports Medicine Market by Type, Revenue
• 4.4. CK
  • 4.4.1. CK market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Myoglobin
  • 4.5.1. Myoglobin market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Lactate
  • 4.6.1. Lactate market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. WBC
  • 4.7.1. WBC market estimates and forecasts 2018 - 2030 (USD Million)
• 4.8. Urea
  • 4.8.1. Urea market estimates and forecasts 2018 - 2030 (USD Million)
• 4.9. CRP
  • 4.9.1. CRP market estimates and forecasts 2018 - 2030 (USD Million)
• 4.10. Lipid and Protein Hydroperoxides
  • 4.10.1. Lipid and protein hydroperoxides market estimates and forecasts 2018 - 2030 (USD Million)
• 4.11. IL-6
  • 4.11.1. IL-6 market estimates and forecasts 2018 - 2030 (USD Million)
• 4.12. Others
  • 4.12.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Blood-based Biomarker for Sports Medicine Market: Regional Estimates & Trend Analysis by Type

• 5.1. Regional Dashboard
• 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.3. North America
  • 5.3.1. U.S.
    • 5.3.1.1. Key country dynamics
    • 5.3.1.2. Regulatory framework/ reimbursement structure
    • 5.3.1.3. Competitive scenario
    • 5.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.3.2. Canada
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.3.3. Mexico
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Regulatory framework/ reimbursement structure
    • 5.3.3.3. Competitive scenario
    • 5.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.3. France
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.6. Norway
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.8. Denmark
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.3. India
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.4. Australia
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.5. New Zealand
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. New Zealand market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.6. Taiwan
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Taiwan market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.7. Hong Kong
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework/ reimbursement structure
    • 5.5.7.3. Competitive scenario
    • 5.5.7.4. Hong Kong market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.8. Singapore
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Regulatory framework/ reimbursement structure
    • 5.5.8.3. Competitive scenario
    • 5.5.8.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.9. Thailand
    • 5.5.9.1. Key country dynamics
    • 5.5.9.2. Regulatory framework/ reimbursement structure
    • 5.5.9.3. Competitive scenario
    • 5.5.9.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.10. Vietnam
    • 5.5.10.1. Key country dynamics
    • 5.5.10.2. Regulatory framework/ reimbursement structure
    • 5.5.10.3. Competitive scenario
    • 5.5.10.4. Vietnam market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6.2. Argentina
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6.3. Chile
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. Chile market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. South Africa
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7.4. Egypt
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. Egypt market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7.5. Qatar
    • 5.7.5.1. Key country dynamics
    • 5.7.5.2. Regulatory framework/ reimbursement structure
    • 5.7.5.3. Competitive scenario
    • 5.7.5.4. Qatar market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Vendor Landscape
  • 6.2.1. List of key distributors and channel partners
  • 6.2.2. Key customers
  • 6.2.3. Key company market share analysis, 2023
  • 6.2.4. Abbott
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. BIOMERIEUX
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. F. Hoffmann-La Roche Ltd.
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. ARUP Laboratories
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. Siemens Healthineers AG
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. RayBiotech, Inc.
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives
  • 6.2.10. Thermo Fisher Scientific, Inc.
    • 6.2.10.1. Company overview
    • 6.2.10.2. Financial performance
    • 6.2.10.3. Product benchmarking
    • 6.2.10.4. Strategic initiatives
  • 6.2.11. Bio-Rad Laboratories, Inc.
    • 6.2.11.1. Company overview
    • 6.2.11.2. Financial performance
    • 6.2.11.3. Product benchmarking
    • 6.2.11.4. Strategic initiatives
  • 6.2.12. Beckman Coulter, Inc.
    • 6.2.12.1. Company overview
    • 6.2.12.2. Financial performance
    • 6.2.12.3. Product benchmarking
    • 6.2.12.4. Strategic initiatives
  • 6.2.13. Randox Laboratories Ltd.
    • 6.2.13.1. Company overview
    • 6.2.13.2. Financial performance
    • 6.2.13.3. Product benchmarking
    • 6.2.13.4. Strategic initiatives

관련자료